Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians

Treatments supported in the updated guidance include the consideration of molnupiravir or nirmatrelvir-ritonavir to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within five days of the onset of symptoms and at a high risk for progressing to severe disease.

Reyna Howkins

COVID-19, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, molnupiravir, nirmatrelvir-ritonavir, ivermectin, sotrovimab, immunity, immunization,

Tue, 09/19/2023 - 9:28 AM EDT

Tue, 09/19/2023 - 9:40 AM EDT

1

practice_point_outpatient_treatment_covid19_2023.pdf

{"Author":"Reyna Howkins","Creator":"Microsoft\u00ae Word for Microsoft 365","CreationDate":"2023-09-19T09:28:00-04:00","ModDate":"2023-09-19T09:40:16-04:00","Producer":"Microsoft\u00ae Word for Microsoft 365","Title":"Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians","Subject":"","Keywords":"COVID-19, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, molnupiravir, nirmatrelvir-ritonavir, ivermectin, sotrovimab, immunity, immunization,","Pages":1}

2023